AZ examining the effects of travel on employees; Pfizer's India unit posts a quarterly dip on plant lockout;

@FiercePharma: Top-read in FiercePharmaMarketing Weds: Sanofi revamps 'underperforming' U.S. sales team under new diabetes chief. Article | Follow @FiercePharma

@EricPFierce: Boehringer Ingelheim unloads US API plant to Chinese company even as it expands in China. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's FiercePharmaMarketing newsletter. Subscribe to get it weekly. | Follow @CarlyHFierce

> AstraZeneca ($AZN) is researching the effects of travel on its employees' well-being to see whether there's is a link to recruitment and retention. More

> Pfizer's ($PFE) Indian unit reported a quarterly loss thanks to expenses related to a lockout at its manufacturing plant in Mumbai. Report

> Swedish drugmaker Meda posted a higher-than-expected third-quarter core profit and raised its margin outlook for 2014. Report

> Jordan's Hikma Pharmaceuticals raised its full-year revenue growth target to 7%, citing strong demand for its high-margin injectible drugs. More

> CEO of Hungarian drugmaker Richter, Erik Bogsch, said the company expects full-year revenues to fall by 5% to 6% from last year, compared with a previous forecast for a 6% to 7% drop. More

> Slovenia's Krka posted a 9-month group net profit of €127.4 million ($159 million), up 2% from the same period last year. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic in high spirits over positive study results for drug-coated balloon. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Government report says device tax will not deter innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Medtronic in high spirits over positive study results for drug-coated balloon. More | Follow @EmilyWFierce

> Dexcom snags FDA approval for next-gen artificial pancreas tech for blood glucose monitoring system. Report

> Stryker agrees to pay $1.43B to settle recalled hip implant lawsuits. Story

> Dozens of lawsuits filed in growing counterfeit spinal screw implant scandal. Article

Biotech News

@FierceBiotech: Merck partners with Bind on a pair of new cancer drug programs. News | Follow @FierceBiotech

@JohnCFierce: Aeterna Zentaris bottoms out after a stinging FDA rejection--$AEZS down 51%. More | Follow @JohnCFierce

@DamianFierce: So $ABBV's not disclosing a PDUFA date for its HCV combo, but its June priority review disclosure puts in mid Dec. June release | Follow @DamianFierce

@EmilyMFierce: Glaxo hep C vaccine delivers promising early results. FierceVaccines story | Follow @EmilyMFierce

> GlaxoSmithKline's effort to re-launch cancer R&D faces skepticism. Item

> Spark snags a 'breakthrough' tag for its Phase III gene therapy. More

> Tolero wraps up a $22.4M round to support its cancer contender. Article

Pharma Manufacturing News

> Two more guilty pleas in spectacular burglary of Lilly warehouse. News

> Valeant labeling snafu affects Sanofi's Aplenzin, as well as Valeant's vaseretic. Report

> Ranbaxy manufacturing mess costs it exclusive for Valcyte generic. More

> Baxter spends $10M expanding admixing facility in Canada. Story

> German meat company invests $30M in plant for traceable heparin ingredients. Article

Vaccines News

> Inhaled Ebola vaccine may provide higher protection rate. News

> Sanofi, armed with more strong PhIII dengue data, sets sights on 2015 rollout. Report

> Glaxo hep C vaccine delivers promising early results. Story

> Sanofi, Protein Sciences win flu jab nods in older adults. Item

> PATH Malaria Vaccines Initiative nets $156M from Gates Foundation. Article

And Finally... Switzerland is distributing iodide tablets to more than half the country's population for use in the event of a nuclear disaster. More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.